Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
Earnings Data
Report Date
Nov 06, 2025TBA (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
2.03Last Year’s EPS
1.61Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call presents a strong financial performance with significant revenue growth and successful execution of strategic priorities, particularly with Jornay PM and the pain portfolio. Despite increased operating expenses and a decline in GAAP net income, the overall business outlook remains positive with raised financial guidance and a strong commitment to shareholder value.Company Guidance -
Q3 2025
Record Quarterly Revenue and Growth
Collegium Pharmaceuticals reported record quarterly revenue of $188 million, a 29% increase year-over-year. Adjusted EBITDA grew by 9% year-over-year, demonstrating strong financial performance across its portfolio.
Significant Growth in Jornay PM
Jornay PM continued to be a lead growth driver with a 23% year-over-year increase in prescriptions and record quarterly revenues of $32.6 million. Market share in the long-acting branded methylphenidate market grew to 23%, up 7.6 percentage points year-over-year.
Pain Portfolio Performance
The pain portfolio generated record revenues of $155.4 million, up 7% year-over-year, with all three core pain medicines showing year-over-year revenue growth.
Share Repurchase Program
Collegium completed a $25 million accelerated share repurchase program and authorized a new $150 million share repurchase program, showcasing commitment to returning value to shareholders.
Raised Financial Guidance
The company raised its 2025 financial guidance, expecting total revenue growth of 19% year-over-year and adjusted EBITDA growth of 12% year-over-year.
COLL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
COLL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 07, 2025 | $29.75 | $32.94 | +10.72% |
May 08, 2025 | $27.27 | $28.89 | +5.94% |
Feb 27, 2025 | $28.42 | $29.05 | +2.22% |
Nov 07, 2024 | $34.71 | $32.16 | -7.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Collegium Pharmaceutical (COLL) report earnings?
Collegium Pharmaceutical (COLL) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).
What is Collegium Pharmaceutical (COLL) earnings time?
Collegium Pharmaceutical (COLL) earnings time is at Nov 06, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is COLL EPS forecast?
COLL EPS forecast for the fiscal quarter 2025 (Q3) is 2.03.